Hyper Acute Pancreas (algenpantucel-L) fails to meet primary endpoint in phase III IMPRESS trial for pancreatic cancer- NewLink Genetics

NewLink Genetics Corporation announced results of its Phase III clinical trial for Hyper Acute Pancreas (algenpantucel-L) for patients with resected pancreatic cancer. The IMPRESS Phase III study of algenpantucel-L for patients with resected pancreatic cancer did not achieve its primary endpoint. Overall survival from time of randomization was 29.3 months for both groups combined. There was no statistically significant difference between the two groups.

The median survival was 30.4 months and 27.3 months for the control and study groups, respectively. There was also no statistical difference for long-term survival. Three year survival was 41.4% and 42.1% and four year survival was 32.6% and 32.7% for the control and study groups, respectively. A total of 722 patients with surgically removed cancers were enrolled at more than 70 sites in the United States from May 2010 to September 2013.